Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Cell Therapeutics files updated Pediatric Investigation Plan for pixantrone to the EMA

July 6, 2010

ADVENTRX reports encouraging 9-month data from stability tests of Exelbine

July 6, 2010

Myriad Pharmaceuticals changes name to Myrexis, will focus on oncology programs

July 6, 2010

Maximum tolerated dose of acadesine identified in chronic lymphocytic leukemia patients

July 6, 2010

Multikinase inhibitor regorafenib evaluated in NSCLC; interim phase I data presented

July 6, 2010

Bruton's tyrosine kinase inhibitors reported by CGI and Genentech

July 6, 2010

Phase III study of Avastin combined with chemotherapy meets primary endpoint

July 5, 2010

FDA grants Cyclacel orphan designation for sapacitabine in AML and MDS

July 5, 2010

Banyu discovers Wee1 kinase inhibitors for cancer therapy

July 5, 2010

Preliminary phase I data on HDAC inhibitor CHR-3996 in advanced solid tumors disclosed

July 5, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...